<DOC>
	<DOCNO>NCT00911170</DOCNO>
	<brief_summary>This phase 3 , randomize , double-blind , placebo-controlled multi-center study evaluate efficacy pegfilgrastim reduce incidence febrile neutropenia ( FN ) patient newly diagnose , locally-advanced metastatic colorectal cancer receive first-line treatment bevacizumab either 5-fluorouracil , Oxaliplatin , Leucovorin ( FOLFOX ) 5-fluorouracil , Irinotecan , Leucovorin ( FOLFIRI ) . This study also investigate effect add pegfilgrastim bevacizumab either FOLFOX FOLFIRI evaluate overall survival , progression-free survival , overall response rate arm regular interval maximum 60 month follow-up .</brief_summary>
	<brief_title>PAVES : Pegfilgrastim Anti-vascular Endothelial Growth Factor ( VEGF ) Evaluation Study</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Diseaserelated : Histologically cytologicallyconfirmed adenocarcinoma colon rectum Locallyadvanced metastatic disease radiographic evaluation Measurable disease Has previously receive chemotherapy locallyadvanced metastatic colorectal cancer . Patient may receive adjuvant therapy primary colorectal cancer provide least 6 month elapse time adjuvant therapy conclude recurrent/metastatic disease document . Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 Demographic : Age 18 year Laboratory : Adequate organ marrow function define : Absolute neutrophil count least 1.5 x 10^9/L Platelet count least 100 x 10^9/L Bilirubin ≤ 1.5 time upper limit normal Aspartate aminotransferase alanine aminotransferase ≤ 2.5 x upper limit normal Aspartate aminotransferase alanine aminotransferase ≤ 5.0 x upper limit normal attributable liver metastasis An inrange international normalize ratio ( INR ) ( inrange usually define 2 3 ) patient stable dose oral anticoagulant stable dose low molecular weight heparin Has active bleed pathological condition carry high risk bleeding ( eg , tumor involve major vessel know varix ) . If suspicion bleed diathesis exists , bleed time perform Creatinine ≤ 1.5 time upper limit normal General : Written inform consent obtain Afebrile day 1 cycle 1 Must able willing comply study and/or followup procedure DiseaseRelated : Known brain metastasis History another primary malignancy less than/equal 5 year prior randomization , exception nonmelanoma skin cancer , carcinoma situ uterine cervix , prostatic intraepithelial neoplasia without evidence prostate cancer Prior major surgical procedure le 28 day prior day 1 cycle 1 chemotherapy dosing ; anticipate need major surgical procedure 4 cycle treatment period study Fine needle aspiration core biopsy within 7 day prior day 1 cycle 1 chemotherapy dose Serious nonhealing wound , ulcer , bone fracture , history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior day 1 cycle 1 Uncontrolled high blood pressure , history labile hypertension , uncontrolled congestive heart failure , unstable angina within past 3 month , myocardial infarction history stroke within past 12 month , unstable symptomatic arrhythmia require medication , clinically significant peripheral vascular disease History clinically significant bleeding within 6 month prior randomization History arterial venous thromboembolism within 6 month prior randomization History disease include uncontrolled diabetes , serious active uncontrolled infection , metabolic dysfunction ; physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use prescribed therapy might affect interpretation result study render subject high risk treatment complication Laboratory : Proteinuria &gt; 1+ , total quantitative protein &gt; 500 mg protein/day determine 24hr urine collection Medications : Prior radiotherapy unless treatment limited target lesion 1 measurable lesion treat . Progression irradiated lesion must demonstrate . Patients may receive prior radiotherapy great 25 % bone marrow . Radiation must conclude ≥ 4 week prior enrollment . Prior radiosensitizing chemoradiation allow long conclude ≥ 4 week prior enrollment . Radiotherapy nontarget lesion pain control allow Prior bevacizumab use agent target VEGF Concurrent use biological agent Use systemic antiinfectives active infection , 3 calendar day start study chemotherapy bevacizumab plan study treatment period General : Current , recent ( within 4 week first infusion study ) , plan participation ( study treatment period ) experimental therapeutic study protocol Female participant pregnant lactate men woman reproductive potential willing employ effective method birth control treatment 20 week woman , 30 week men discontinue study treatment History allergic reaction attribute compound similar chemical biologic composition bevacizumab , irinotecan , 5fluorouracil ( 5FU ) , oxaliplatin , leucovorin , include know sensitivity E. Coli derive product ( eg , Filgrastim , HUMULIN insulin , Lasparaginase ) Known dihydropyrimidine dehydrogenase deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>adenocarcinoma colon rectum</keyword>
	<keyword>febrile neutropenia</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>5-fluorouracil , Oxaliplatin , Leucovorin ( FOLFOX )</keyword>
	<keyword>5-fluorouracil , Irinotecan , Leucovorin ( FOLFIRI )</keyword>
</DOC>